medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2013, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (2)

Treatment of children acute myeloid leukemia in Cuba

Menéndez VA, González OA, Svarch E, Rosell ME, Campo DM, Arencibia NA, Machín GS, Martínez CL, Jaime FJC, Márquez HE, Lam DRM

Language: Spanish
References: 17
Page:
PDF size: 56. Kb.


ABSTRACT

Introduction. acute myeloid leukemia represents about 20 % of all leukemias in childhood with results and survival smaller than in acute lymphoid leukemia.
Objectives: to describe the results obtained with the treatment of acute myeloid leukemia in children in some Cuban centers in from 2000 to 2008.
Methods: forty-six patients from Western provinces of Cuba including Sancti Spiritus and Villa Clara were treated. The majority of the patients were males. The median age was 9 years old. Two periods of treatment were applied, the first from 2000 to 2003 with 27 patients; and the second from 2004 to 2008 with 19 cases. The difference between the two periods was that in the second one the consolidation had short and intensive cycles.
Results: the initial remission was 71 % in the first period and 89 % in the second. Free survival was 40 % in 5 years and the overall survival (OS) was 44 %, but in the first period the OS was 30,8 % and in the second it was 63,2 %. Immunophenotype and cytogenetic and molecular alterations were studied only in 10 children. Hematopoietic transplantation was not performed sytematically.
Conclusions: these results show a level comparable to those achieved internationally, representing a major achievement of the Cuban National Health System.


REFERENCES

  1. Pui CH. Childhood leukemias. N Engl J Med. 1995 Jun 15;332(24):1618-30.

  2. Löwenberg B, Griffing JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia . Hematology Am Soc Hematol Educ Program. 2003:82-101.

  3. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood.2009;114(6):1150-7.

  4. Puig H, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011 Feb 10;29(5):551-65.

  5. Bennett JC, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985 Oct;103(4):620-5.

  6. Rubinitz JE. How I treat pediatric acute myeloid leukemia.Blood.2012; 119(25):5980-8.

  7. Guidelines for the pediatric cancer center and role of such centers in diagnosis and treatment. American Academy of Pediatrics Section Statement Section on Hematology/Oncology. Pediatrics. 1997 Jan;99(1):139-41.

  8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al :The 2008 revision of the World Health Organization ( WHO) classification of myeloid neoplasm and acute leukemias and important changes . Blood. 2009 Jul 30;114(5):937-51.

  9. Fellini B, Tiacci E, Martelli MP, Ascani S, Pileri SA. New classification of acute myeloid leukemia and precursor- related neoplasms: changes and unsolved issues. Discov Med. 2010 Oct; 10 (53): 281-92.

  10. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126-35.

  11. Creutzig U, Ritter J, Schellong G. Identification of two risk group in childhood acute myelogenous leukaemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78 AML-BFM Study Group . Blood. 1990 May 15;75(10):1932-40.

  12. Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D. Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma.2009;9(suppl 3):S281-5.

  13. Ebb DH, Weinstein HJ. Diagnosis and treatment of childhood acute myelogenous leukaemia . Pediatr Clin North Am. 1997 Aug;44(4):847-62.

  14. Creutzig U, Van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, De Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012 Aug 9;120:3187-205.

  15. Creutzig U. Risk adapted treatment in Pediatric AML. 3rd International Congress on Leukemia Lymphoma Myeloma. 2011 may 11-14 Istanbul, Turkey. Proceedings & Abstract Book. p. 210-2.

  16. Gibson B. The place of stem cell transplantation in 1st remission in Pediatric AML. 3rd International Congress on Leukemia Lymphoma Myeloma. 2011 may 11-14 Istanbul, Turkey. Proceedings & Abstract Book. p 200-3.

  17. Creutzig U; Zimmermann M; Bourquin J P; Dworzak MN; Kremens B; Lehrnbecher; et al. Favorable outcome in infants with AML after intensive first-and second- line treatment: an AML-BFM study group report. Leukemia 2012 apr; 26(4): 654-61.




2020     |     www.medigraphic.com